The ‘Open Innovation Stage,’ an early-stage promising bioventure support program, was set up at ‘BioPlus-Interphex Korea 2023,’ organized by the Incheon Free Economic Zone Authority(IFEZ) and the Korea Bio Association. The event took place from July 12th to 14th. On the first day of the event, a total of six domestic bio-healthcare tech companies pitched their ideas to institutional investors (FIs), including venture capitalists, and discussed their investment intentions.
Among the pitching companies, six were supported by Incheon-based MUST Accelerator. Three of them were pharmaceutical-bio companies (Microbiotix, INEXOPLAT, Portrai), two were healthcare-diagnosis-medical equipment companies (Neurive and AIinsight), and one was a bio-process equipment company (ABLE Labs).
INEXOPLAT (represented by Kim Sung-hwan) explained the differentiation of its exosome-based immune cancer therapy (IEP01) from conventional immune cancer therapies and introduced its pipeline targeting solid tumors. By presenting IEP01 as a solution surpassing the limitations of current immune cancer therapies, INEXOPLAT raised investors’ expectations.
Source: The Bell (https://www.thebell.co.kr/free/Content/ArticleView.asp?key=202307121507296880104767&svccode=)